Market Place
Sourcing Support
Lantheus` Phase 3 Radiotherapy Results Fail To Surpass Pluvicto
16 Sep 2024 //
FIERCE BIOTECH
Lantheus Announces CEO Succession Plan
23 Jan 2024 //
PRESS RELEASE
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA
11 Jan 2024 //
PRESS RELEASE
42nd Annual J.P. Morgan Healthcare Conference
10 Jan 2024 //
PRESS RELEASE
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
09 Jan 2024 //
PRESS RELEASE
Lantheus Expands Radiopharmaceutical Oncology Pipeline
09 Jan 2024 //
PRESS RELEASE
Lantheus hands Perspective $28M upfront to expand its radiopharma options
09 Jan 2024 //
ENDPTS
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PRESS RELEASE
POINT Biopharma shareholders get long-awaited radioligand therapy data
20 Dec 2023 //
PRESS RELEASE
Lantheus and POINT Biopharma Announce Positive Results from SPLASH Trial
18 Dec 2023 //
GLOBENEWSWIRE
Lantheus Announces Presentations Featuring PYLARIFY AI at Society for SNMMI
12 Jun 2023 //
PRESS RELEASE
Lantheus to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
PRESS RELEASE
Lantheus nabs Cerveau and its tau PET tracer for Alzheimer`s
08 Feb 2023 //
FIERCE BIOTECH
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
20 Dec 2022 //
GLOBENEWSWIRE
Lantheus Announces Pricing of Offering of $500M Convertible Senior Notes
06 Dec 2022 //
PRESS RELEASE
Lantheus Announces Appointment of Amanda Morgan as Senior VP
29 Nov 2022 //
PRESS RELEASE
Lantheus Announces the Approval of DEFINITY by China’s NMPA
28 Nov 2022 //
PRESS RELEASE
Lantheus pledges up to $2B for 2 of POINT`s radiopharmaceuticals
15 Nov 2022 //
FIERCEBIOTECH
Lantheus and POINT Biopharma Announce Strategic Collaboration
14 Nov 2022 //
PRESS RELEASE
Lantheus to Present at the Jefferies London Healthcare Conference
09 Nov 2022 //
PRESS RELEASE
Lantheus Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRESS RELEASE
Lantheus Holdings Slides 11%
07 Oct 2022 //
NASDAQ
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on Nov3
01 Oct 2022 //
PRESS RELEASE
GE & Lantheus Finds flurpiridaz Improves Detection of Coronary Artery Disease
13 Sep 2022 //
BUSINESSWIRE
Lantheus to Present at the Wells Fargo Healthcare Conference
01 Sep 2022 //
PRESS RELEASE
Curium Submits MAA for [18F]-DCFPyL to the EMA
27 Jun 2022 //
GLOBENEWSWIRE
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
29 Apr 2022 //
PRESS RELEASE
Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call
25 Apr 2022 //
PRESS RELEASE
Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer
04 Apr 2022 //
PRESS RELEASE
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
29 Mar 2022 //
PRESS RELEASE
Lantheus Holdings to Present at the Barclays Global Healthcare Conference
08 Mar 2022 //
PRESS RELEASE
Lantheus to Host Inaugural Investor Day
03 Mar 2022 //
PRESS RELEASE
Lantheus Appoints Minnie Baylor-Henry as New Board Member
01 Mar 2022 //
PRESS RELEASE
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY
22 Nov 2021 //
GLOBENEWSWIRE
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
29 Jul 2021 //
BUSINESSWIRE
Lantheus Gets First FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE
29 Jul 2021 //
BUSINESSWIRE
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call
14 Jul 2021 //
BUSINESS WIRE
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call
14 Jul 2021 //
BUSINESS WIRE
Lantheus To Present Piflufolastat F 18 Data at the Virtual SNMM 2021
14 Jun 2021 //
BUSINESSWIRE
Lantheus To Present Piflufolastat F 18 Data at Virtual SNMMI 2021 Annual Meeting
14 Jun 2021 //
BUSINESSWIRE
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection
27 May 2021 //
BUSINESSWIRE
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection
27 May 2021 //
BUSINESSWIRE
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT
21 May 2021 //
BUSINESSWIRE
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
04 May 2021 //
BUSINESSWIRE
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast
30 Mar 2021 //
BUSINESSWIRE
Lantheus Announces Presentation Featuring AZEDRA®
22 Mar 2021 //
BUSINESSWIRE
Lantheus Announces Presentations Featuring its PSMA-Targeted Pipeline Product
04 Feb 2021 //
BUSINESSWIRE
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
12 Jan 2021 //
BUSINESSWIRE
